ClinicalTrials.gg
CompletedNCT02551159KESTRELUpdated Oct 13, 2021Results posted

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

A Phase 3 interventional study of MEDI4736 and Tremelimumab in Squamous Cell Carcinoma of the Head and Neck, sponsored by AstraZeneca. Completed at 197 sites in 23 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-10-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
823
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck — none open to participants now, 3 under way, none of them phase 3. durvalumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
Largest of 20
823 · median 40
Started
2015
the only one that year
Phase 3
2 of 20
none open now
Registered
3rd of 20
by date
Lead sponsor
4 of 20
AstraZeneca

Among the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck, this one has the largest enrollment, is the only one that started in 2015, is one of 2 in phase 3, and was the 3rd registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

None of the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck is open now. The open studies under Squamous Cell Carcinoma of Head and Neck, anywhere →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing durvalumab in Squamous Cell Carcinoma of Head and Neck as a file.
02

Study summary

This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of patients with SCCHN who have not received prior systemic chemotherapy for recurrent or metastatic disease.

Read the detailed description

Patients will be randomized in a 2:1:1 ratio to MEDI4736 + tremelimumab combination therapy, MEDI4736 monotherapy, or SoC. Patients in all arms will continue therapy until progression. Tumor assessments will be performed on computed tomography scans or magnetic resonance imaging scans, preferably with intravenous (IV) contrast. Efficacy for all patients will be assessed by objective tumor assessments every 6 weeks for the first 24 weeks, then every 8 weeks thereafter until treatment discontinuation due to progression or toxicity. All patients will be followed every 3 months for survival after progression is confirmed.

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck

Keywords

  • programmed cell death ligand 1 (PD-L1), MEDI4736, Cytotoxic T-lymphocyte-associated antigen 4 {CTLA-4}, PFS, SCCHN
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years at the time of screening
  2. Documented evidence of recurrent or SCCHN (oral cavity, oropharynx, hypopharynx, or larynx).
  3. A fresh tumor for the purpose of screening or an available archival tumor sample. Tumor lesions used for fresh biopsies should not be the same lesions used as target lesions, unless there are no other lesions suitable for biopsy.
  4. No prior systemic chemotherapy for recurrent or metastatic disease
  5. World Health Organization (WHO)/ (ECOG) performance status of 0 or 1 at enrollment
  6. No prior exposure to immune-mediated therapy,

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including patients with SCCHN of unknown primary or non-squamous histologies (eg, nasopharynx or salivary gland)
  2. Tumor progression or recurrence within 6 months of last dose of platinum therapy in the primary treatment setting
  3. Receipt of any radiotherapy or hormonal therapy for cancer treatment within 30 days prior to first dose of study treatment
  4. Active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis, Crohn's disease], diverticulitis
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
823 participants (actual)

Study arms

  • Experimental
    Monotherapy

    MEDI4736 monotherapy.

    Biological: MEDI4736

  • Experimental
    Combination Therapy

    MEDI4736+Tremelimumab combination therapy

    Biological: Tremelimumab · Biological: MEDI4736+Tremelimumab

  • Active comparator
    Standard of Care

    Standard of Care treatment

    Biological: Cetuximab · Drug: 5-fluorouracil (5FU) · Drug: Cisplatin · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC)

    Number of participants with Overall Survival (OS)

    Time frame: From date of randomization until time of final analysis, an average of approximately 4 years

  2. Overall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup

    Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)

    Time frame: From date of randomization until time of final analysis, an average of approximately 4 years

Secondary outcomes

  1. Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab + Tremelimumab Versus Standard of Care (SOC)

    Number of participants with Overall Survival (OS)

    Time frame: From date of randomization until time of final analysis, an average of approximately 4 years

  2. Percentage of Patients Alive at 12, 18 and 24 Months in the PD-L1 TC/IC High Subgroup

    Percentage of patients alive

    Time frame: 12, 18 and 24 months after randomization

  3. Progression Free Survival (PFS) in the PD-L1 TC/IC High Subgroup

    Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years

  4. Objective Response Rate (ORR) in the PD-L1 TC/IC High Subgroup

    Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: \>= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years

  5. Duration of Response (DoR) in the PD-L1 TC/IC High Subgroup

    Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years

  6. Overall Survival (OS) Status in the All-comers (Full Analysis Set)

    Number of participants with Overall Survival (OS)

    Time frame: From date of randomization until time of final analysis, an average of approximately 4 years

  7. Overall Survival (OS) Median Duration in the All-comers (Full Analysis Set)

    Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)

    Time frame: From date of randomization until time of final analysis, an average of approximately 4 years

  8. Percentage of Patients Alive at 12, 18 and 24 Months in the All-comers (Full Analysis Set)

    Percentage of patients alive

    Time frame: 12, 18 and 24 months after randomization

  9. Progression Free Survival (PFS) in the All-comers (Full Analysis Set)

    Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years

  10. Objective Response Rate (ORR) in the All-comers (Full Analysis Set)

    Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: \>= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years

  11. Duration of Response (DoR) in the All-comers (Full Analysis Set)

    Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years

07

Results

Posted Oct 13, 2021

Participant flow

Patients meeting all the eligibility criteria were randomized 2:1:1 to durvalumab plus tremelimumab combination therapy, durvalumab monotherapy or standard of care.

Participant flow — Overall Study
MilestoneDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
Started413204206
Full analysis set413204206
Safety analysis set408202196
Pd-l1 tc/ic high subgroup analysis set1909994
Completed000
Not completed413204206
Withdrew: Death352174161
Withdrew: Withdrawal by subject8516
Withdrew: Patients alive or lost to follow-up at dco532529

Outcome measures

PrimaryOverall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC)

Number of participants with Overall Survival (OS)

Time frame:
From date of randomization until time of final analysis, an average of approximately 4 years
Reported as:
Count of participants · Participants
Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC)
ParticipantsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
Death1628477
Voluntary Discontinuation by subject113
Alive or lost to follow up271414
Statistical analysis
  • Durvalumab vs Standard of Care (SOC) · Log Rank · p = 0.787 (2 sided) · Hazard ratio (hr): 0.96 · 95% CI 0.69 to 1.32
PrimaryOverall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup

Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)

Time frame:
From date of randomization until time of final analysis, an average of approximately 4 years
Reported as:
Median · Months
Overall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
Overall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup11.2 (9.5 to 13.9)10.9 (9.0 to 14.3)10.9 (8.3 to 13.4)
SecondaryOverall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab + Tremelimumab Versus Standard of Care (SOC)

Number of participants with Overall Survival (OS)

Time frame:
From date of randomization until time of final analysis, an average of approximately 4 years
Reported as:
Count of participants · Participants
Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab + Tremelimumab Versus Standard of Care (SOC)
ParticipantsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab + Tremelimumab Versus Standard of Care (SOC)1628477
Statistical analysis
  • Durvalumab + Tremelimumab vs Standard of Care (SOC) · Log Rank · p = 0.634 (2 sided) · Hazard ratio (hr): 1.05 · 95% CI 0.80 to 1.39
SecondaryPercentage of Patients Alive at 12, 18 and 24 Months in the PD-L1 TC/IC High Subgroup

Percentage of patients alive

Time frame:
12, 18 and 24 months after randomization
Reported as:
Number · % of participants
Percentage of Patients Alive at 12, 18 and 24 Months in the PD-L1 TC/IC High Subgroup
% of participantsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
at 12 months49.3 (42.0 to 56.2)48.0 (37.8 to 57.4)44.0 (33.6 to 53.8)
at 18 months31.8 (25.3 to 38.5)34.7 (25.5 to 44.1)30.8 (21.6 to 40.4)
at 24 months23.9 (18.0 to 30.1)27.6 (19.2 to 36.6)26.4 (17.8 to 35.7)
SecondaryProgression Free Survival (PFS) in the PD-L1 TC/IC High Subgroup

Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
Reported as:
Median · Months
Progression Free Survival (PFS) in the PD-L1 TC/IC High Subgroup
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
Progression Free Survival (PFS) in the PD-L1 TC/IC High Subgroup2.8 (2.6 to 3.3)2.8 (1.7 to 4.2)5.3 (4.3 to 5.8)
Statistical analysis
  • Durvalumab vs Standard of Care (SOC) · Log Rank · p = 0.287 (2 sided) · Hazard ratio (hr): 1.30 · 95% CI 0.94 to 1.80
  • Durvalumab + Tremelimumab vs Standard of Care (SOC) · Log Rank · p = 0.028 (2 sided) · Hazard ratio (hr): 1.32 · 95% CI 0.99 to 1.76
SecondaryObjective Response Rate (ORR) in the PD-L1 TC/IC High Subgroup

Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: \>= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) in the PD-L1 TC/IC High Subgroup
ParticipantsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
Response481647
No response1428347
Statistical analysis
  • Durvalumab vs Standard of Care (SOC) · Regression, Logistic · p = <0.001 (2 sided) · Odds ratio (or): 0.19 · 95% CI 0.10 to 0.37
  • Durvalumab + Tremelimumab vs Standard of Care (SOC) · Regression, Logistic · p = <0.001 (2 sided) · Odds ratio (or): 0.34 · 95% CI 0.20 to 0.57
SecondaryDuration of Response (DoR) in the PD-L1 TC/IC High Subgroup

Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
Reported as:
Median · Months
Duration of Response (DoR) in the PD-L1 TC/IC High Subgroup
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
Duration of Response (DoR) in the PD-L1 TC/IC High Subgroup6.5 (4.5 to 16.1)12.3 (5.6 to NA)4.2 (3.0 to 5.7)
SecondaryOverall Survival (OS) Status in the All-comers (Full Analysis Set)

Number of participants with Overall Survival (OS)

Time frame:
From date of randomization until time of final analysis, an average of approximately 4 years
Reported as:
Count of participants · Participants
Overall Survival (OS) Status in the All-comers (Full Analysis Set)
ParticipantsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
Death356176171
Voluntary Discontinuation by subject436
Alive or lost to follow up532529
Statistical analysis
  • Durvalumab vs Standard of Care (SOC) · Log Rank · p = 0.811 (2 sided) · Hazard ratio (hr): 1.03 · 95% CI 0.83 to 1.27
  • Durvalumab + Tremelimumab vs Standard of Care (SOC) · Log Rank · p = 0.624 · Hazard ratio (hr): 1.04 · 95% CI 0.87 to 1.25
SecondaryOverall Survival (OS) Median Duration in the All-comers (Full Analysis Set)

Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)

Time frame:
From date of randomization until time of final analysis, an average of approximately 4 years
Reported as:
Median · Months
Overall Survival (OS) Median Duration in the All-comers (Full Analysis Set)
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
Overall Survival (OS) Median Duration in the All-comers (Full Analysis Set)10.7 (9.6 to 12.2)9.9 (8.9 to 11.9)10.3 (9.0 to 12.1)
SecondaryPercentage of Patients Alive at 12, 18 and 24 Months in the All-comers (Full Analysis Set)

Percentage of patients alive

Time frame:
12, 18 and 24 months after randomization
Reported as:
Number · % of participants
Percentage of Patients Alive at 12, 18 and 24 Months in the All-comers (Full Analysis Set)
% of participantsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
at 12 months46.5 (41.6 to 51.2)42.8 (35.9 to 49.5)43.8 (36.8 to 50.5)
at 18 months30.7 (26.3 to 35.2)31.2 (24.9 to 37.7)29.7 (23.5 to 36.1)
at 24 months22.9 (18.9 to 27.0)24.7 (18.9 to 30.8)23.2 (17.6 to 29.2)
SecondaryProgression Free Survival (PFS) in the All-comers (Full Analysis Set)

Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
Reported as:
Median · Months
Progression Free Survival (PFS) in the All-comers (Full Analysis Set)
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
Progression Free Survival (PFS) in the All-comers (Full Analysis Set)2.8 (2.6 to 2.9)2.8 (2.0 to 2.8)5.4 (4.4 to 5.7)
Statistical analysis
  • Durvalumab vs Standard of Care (SOC) · Log Rank · p = 0.006 (2 sided) · Hazard ratio (hr): 1.36 · 95% CI 1.10 to 1.68
  • Durvalumab + Tremelimumab vs Standard of Care (SOC) · Log Rank · p = 0.008 (2 sided) · Hazard ratio (hr): 1.27 · 95% CI 1.06 to 1.53
SecondaryObjective Response Rate (ORR) in the All-comers (Full Analysis Set)

Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: \>= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) in the All-comers (Full Analysis Set)
ParticipantsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
Response9035101
No response323169105
Statistical analysis
  • Durvalumab vs Standard of Care (SOC) · Regression, Logistic · p = <0.001 (2 sided) · Odds ratio (or): 0.21 · 95% CI 0.13 to 0.33
  • Durvalumab + Tremelimumab vs Standard of Care (SOC) · Regression, Logistic · p = <0.001 (2 sided) · Odds ratio (or): 0.29 · 95% CI 0.20 to 0.41
SecondaryDuration of Response (DoR) in the All-comers (Full Analysis Set)

Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
Reported as:
Median · Months
Duration of Response (DoR) in the All-comers (Full Analysis Set)
MonthsDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
Duration of Response (DoR) in the All-comers (Full Analysis Set)9.2 (6.0 to 19.6)11.9 (4.6 to 17.8)4.2 (3.7 to 4.5)

Adverse events

Collected over Adverse events and serious adverse events will be collected from the time of signature of informed consent throughout the treatment period and including the follow-up period (up to 90 days after the last dose of investigational product or until initiation of another therapy) for an average of approximately 4 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab + Tremelimumab356/413 (86.2%)168/408 (41.2%)317/408 (77.7%)
Durvalumab176/204 (86.3%)78/202 (38.6%)153/202 (75.7%)
Standard of Care (SOC)171/206 (83%)94/196 (48%)182/196 (92.9%)
Most frequent serious events
Showing 10 of 234
Most frequent serious events
EventDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
PneumoniaInfections and infestations32/40814/20213/196
Febrile neutropeniaBlood and lymphatic system disorders0/4080/2028/196
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/4087/2020/196
ThrombocytopeniaBlood and lymphatic system disorders0/4080/2025/196
NeutropeniaBlood and lymphatic system disorders1/4081/2025/196
DysphagiaGastrointestinal disorders6/4081/2025/196
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/4080/2025/196
DiarrhoeaGastrointestinal disorders9/4082/2024/196
Mucosal inflammationGeneral disorders0/4080/2024/196
LeukopeniaBlood and lymphatic system disorders0/4080/2024/196
Most frequent other events
Showing 10 of 48
Most frequent other events
EventDurvalumab + TremelimumabDurvalumabStandard of Care (SOC)
RashSkin and subcutaneous tissue disorders50/40817/20281/196
NauseaGastrointestinal disorders52/40813/20274/196
AnaemiaBlood and lymphatic system disorders61/40822/20265/196
NeutropeniaBlood and lymphatic system disorders2/4080/20263/196
DiarrhoeaGastrointestinal disorders70/40815/20260/196
FatigueGeneral disorders66/40835/20256/196
ConstipationGastrointestinal disorders59/40824/20254/196
Decreased appetiteMetabolism and nutrition disorders52/40820/20246/196
HypomagnesaemiaMetabolism and nutrition disorders11/4083/20245/196
Mucosal inflammationGeneral disorders15/4086/20243/196

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Durvalumab + TremelimumabDurvalumabStandard of Care (SOC)Total
Mean60.5 ± 9.5660.2 ± 10.4160.9 ± 9.4560.5 ± 9.74
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab + TremelimumabDurvalumabStandard of Care (SOC)Total
Female732932134
Male340175174689
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab + TremelimumabDurvalumabStandard of Care (SOC)Total
White298145160603
Black or African American53210
Asian1095442205
Other0224
Missing1001
08

Study locations

197 sites
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Washington, District of Columbia 20007, United States
  • Research Site
    Fort Myers, Florida 33916, United States
  • Research Site
    Saint Petersburg, Florida 33705, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Baltimore, Maryland 21231, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Morristown, New Jersey 07960, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Winston-Salem, North Carolina 27157, United States
  • Research Site
    Cleveland, Ohio 44115, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Linz, 4010, Austria
  • Research Site
    Wien, 1140, Austria
  • Research Site
    Brussels, 1000, Belgium
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Curitiba, 81520-060, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Ijui, 98700-000, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Porto Alegre, 90619-900, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Recife, 50040-000, Brazil
  • Research Site
    Rio de Janeiro, 22793-080, Brazil
  • Research Site
    Santo Andre, 09080-110, Brazil
  • Research Site
    Santo André, 09060-650, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 03102-002, Brazil
  • Research Site
    Calgary, Alberta T2N 4N2, Canada
  • Research Site
    Winnipeg, Manitoba R3E 0V9, Canada
  • Research Site
    Moncton, New Brunswick E1C 8X3, Canada
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
  • Research Site
    London, Ontario N6A 4L6, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Brest, 29200, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Lyon Cedex 08, 69373, France
  • Research Site
    Nice, 06100, France
  • Research Site
    Paris, 75015, France
  • Research Site
    Poitiers Cedex, 86021, France
  • Research Site
    Toulouse Cedex, 31059, France
  • Research Site
    Vandoeuvre les Nancy, 54519, France
  • Research Site
    Villejuif, 94800, France
  • Research Site
    Berlin, 12203, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Essen, 45147, Germany
  • Research Site
    Frankfurt am Main, 60590, Germany
  • Research Site
    Freiburg, 79106, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Würzburg, 97070, Germany
  • Research Site
    Athens, 115 22, Greece
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Athens, 124 61, Greece
  • Research Site
    Athens, 18547, Greece
  • Research Site
    Heraklion, 711 11, Greece
  • Research Site
    Thessaloniki, 54645, Greece
  • Research Site
    Bangalore, 560027, India
  • Research Site
    Bangalore, 560076, India
  • Research Site
    Bengaluru, 560076, India
  • Research Site
    Gurgaon, 122001, India
  • Research Site
    Karamsad, 388325, India
  • Research Site
    Madurai, 625107, India
  • Research Site
    Pune, 411001, India
  • Research Site
    Cona, 44124, Italy
  • Research Site
    Firenze, 50134, Italy
  • Research Site
    Messina, 98158, Italy
  • Research Site
    Milano, 20133, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Palermo, 90127, Italy
  • Research Site
    Salerno, 84131, Italy
  • Research Site
    Siena, 53100, Italy
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Akashi-shi, 673-8558, Japan
  • Research Site
    Chiba-shi, 260-8717, Japan
  • Research Site
    Fukuoka-shi, 811-1347, Japan
  • Research Site
    Hirakata-shi, 573-1191, Japan
  • Research Site
    Isehara-shi, 259-1193, Japan
  • Research Site
    Kagoshima-shi, 890-8520, Japan
  • Research Site
    Kanazawa-shi, 920-8650, Japan
  • Research Site
    Kitaadachi-gun, 362-0806, Japan

Showing the first 100 of 197 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hwang M, Seiwert TY. Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era. Lancet Oncol. 2021 Apr;22(4):413-415. doi: 10.1016/S1470-2045(21)00121-2. Epub 2021 Mar 5. No abstract available. Erratum In: Lancet Oncol. 2021 Apr;22(4):e134. doi: 10.1016/S1470-2045(21)00140-6. PubMed 33684371 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Jul 2020, 56 months.

Results were first posted in Oct 2021, 1 year 3 months after primary completion.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's 56 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2015
First posted
Sep 16, 2015
StartActual
Oct 15, 2015
Primary completionActual
Jul 6, 2020
CompletionActual
May 21, 2021
Results first posted
Oct 13, 2021
Last update
Oct 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02551159
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 16, 2015
Start date
Oct 15, 2015
Primary completion
Jul 6, 2020
Completion
May 21, 2021
Results posted
Oct 13, 2021
Last update
Oct 13, 2021

Study contacts

Richard Olsson
study director
Tanguy Seiwert
principal investigator · The University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion